Syntegon improved its revenue by ten percent to 1.75 billion euros in fiscal year 2025. Order intake rose to 1.86 billion euros, providing a solid foundation for future growth. Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew by 27 percent to 282 million euros. “2025 marks a year of outstanding performance for Syntegon. We made significant progress in our transformation into a leading strategic lifecycle partner for our customers, and in elevating our operational excellence. As a result, Syntegon today operates a strong, scalable value creation platform and has set course for sustainable, long-term profitable growth,” emphasizes Torsten Türling, CEO of Syntegon. “As a result, Syntegon now has a strong, scalable value creation platform and has set the course for sustainable, long-term profitable growth.”
Syntegon benefits from growth in core markets
This positive development is based on a consistently implemented growth strategy in structurally growing markets. Higher volumes in high-margin segments, improved project execution, and an optimized global production structure contributed to the increase in earnings. Additional momentum came from the establishment of an engineering hub in India as well as productivity gains at the plants.
Investments strengthen Syntegon’s position
In 2025, the manufacturer made targeted investments in capacity, new developments, and infrastructure. These include a new Business Excellence Center in Stuttgart and a Pharma-Solid plant in Fellbach. A total of 56 million euros was invested in research and development. These measures lay the foundation for future innovations and support the scalability of the business model. “Across all key financial metrics, order intake, sales, profitability, and cash flow, we delivered meaningful improvements while maintaining a disciplined approach to investment and capital allocation. The consistent progress confirms that our strategy is firmly embedded in our operations and in the way we create value,” adds Eros Carletti, CFO of Syntegon.
Syntegon continues to expand its pharmaceutical business
The pharmaceutical business performed particularly strongly, recording revenue growth of 22 percent. Drivers include new developments in biotechnology as well as rising demand for solutions for injectable therapies. With the acquisition of Telstar, Syntegon has expanded its portfolio and strengthened its position in the area of end-to-end solutions. The service business also performed well, as customers increasingly focus on efficiency gains and the modernization of existing facilities.
Innovations strengthen market position
In the past fiscal year, Syntegon introduced new technologies, including the “SynTiso” filling line. The solution enables glove-free high-speed filling for liquid pharmaceuticals and reduces contamination risks. The innovation met with market demand and received initial orders from pharmaceutical companies. At the same time, the food business also developed positively, driven in part by the SVX platform.
Sustainability as part of strategy of Syntegon
Sustainability remains a central component of the corporate strategy. Syntegon was awarded the Ecovadis Platinum medal in 2025, placing it among the companies evaluated with high sustainability performance. For 2026, Syntegon is aiming for further growth and increased profitability.
